Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Sci Rep ; 11(1): 13592, 2021 06 30.
Article in English | MEDLINE | ID: covidwho-1387484


With global demand for SARS-CoV-2 testing ever rising, shortages in commercially available viral transport media pose a serious problem for laboratories and health care providers. For reliable diagnosis of SARS-CoV-2 and other respiratory viruses, executed by Real-time PCR, the quality of respiratory specimens, predominantly determined by transport and storage conditions, is crucial. Therefore, our aim was to explore the reliability of minimal transport media, comprising saline or the CDC recommended Viral Transport Media (HBSS VTM), for the diagnosis of SARS-CoV-2 and other respiratory viruses (influenza A, respiratory syncytial virus, adenovirus, rhinovirus and human metapneumovirus) compared to commercial products, such as the Universal Transport Media (UTM). We question the assumptions, that the choice of medium and temperature for storage and transport affect the accuracy of viral detection by RT-PCR. Both alternatives to the commercial transport medium (UTM), HBSS VTM or saline, allow adequate detection of SARS-CoV-2 and other respiratory viruses, regardless of storage temperatures up to 28 °C and storage times up to 28 days. Our study revealed the high resilience of SARS-CoV-2 and other respiratory viruses, enabling proper detection in clinical specimens even after long-time storage at high temperatures, independent of the transport medium's composition.

COVID-19 Nucleic Acid Testing/methods , COVID-19/diagnosis , Culture Media/chemistry , Preservation, Biological/methods , SARS-CoV-2/genetics , Specimen Handling/methods , Virology/methods , Cold Temperature , Humans , Laboratory Chemicals/chemistry , Reproducibility of Results , Time Factors
Transfusion ; 60(9): 1905-1909, 2020 09.
Article in English | MEDLINE | ID: covidwho-613577


New York is at the epicenter of the coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus. Columbia University Irving Medical Center/NewYork-Presbyterian Hospital (CUIMC/NYPH) had to make changes to its cellular therapy operations to ensure patient, donor, and staff safety and well-being. In this article, we discuss the process changes we instituted for cellular therapy clinical care, collection, processing, and cryopreservation to cope with the rapidly evolving pandemic.

Academic Medical Centers , COVID-19/epidemiology , Cell- and Tissue-Based Therapy/statistics & numerical data , Pandemics , SARS-CoV-2 , Academic Medical Centers/organization & administration , Academic Medical Centers/statistics & numerical data , Adult , Bone Marrow Transplantation/methods , Bone Marrow Transplantation/statistics & numerical data , COVID-19 Testing , Cell Separation/methods , Child , Clinical Trials as Topic/organization & administration , Cryopreservation/methods , Donor Selection , Humans , Immunotherapy, Adoptive/methods , Immunotherapy, Adoptive/statistics & numerical data , Lymphocyte Transfusion/methods , Lymphocyte Transfusion/statistics & numerical data , New York City/epidemiology , Organ Preservation/methods , Peripheral Blood Stem Cell Transplantation/methods , Peripheral Blood Stem Cell Transplantation/statistics & numerical data , Preservation, Biological/methods , Procedures and Techniques Utilization , Tissue Donors , Tissue and Organ Procurement/methods , Tissue and Organ Procurement/organization & administration